Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2024 Aug 13

PMID 39137766

Authors

Kashmira Date

Christopher LeBoa

Seth A Hoffman

Pradeep Haldar

Pauline Harvey

Qian An

Chenhua Zhang

Vijay N Yewale

Savita Daruwalla

Dhanya Dharmapalan

Jeetendra Gavhane

Shrikrishna Joshi

Rajesh Rai

Varsha Rathod

Keertana Shetty

Divyalatha S Warrier

Shalini Yadav

Rahul Shimpi

Niniya Jayaprasad

Lily Horng

Kirsten Fagerli

Priyanka Borhade

Debjit Chakraborty

Arun Katkar

Abhishek Kunwar

Jason R Andrews

Sunil Bahl

Pankaj Bhatnagar

Shanta Dutta

Stephen P Luby

Affiliations

Soon will be listed here.

Abstract

Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.

References

Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas P, Bhuiyan A . Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021; 398(10301):675-684. PMC: 8387974. DOI: 10.1016/S0140-6736(21)01124-7. View

Cornfield J . A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst. 1951; 11(6):1269-75. View

Kim C, Goucher G, Tadesse B, Lee W, Abbas K, Kim J . Associations of water, sanitation, and hygiene with typhoid fever in case-control studies: a systematic review and meta-analysis. BMC Infect Dis. 2023; 23(1):562. PMC: 10464135. DOI: 10.1186/s12879-023-08452-0. View

Hoffman S, LeBoa C, Date K, Haldar P, Harvey P, Shimpi R . Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India. Clin Infect Dis. 2023; 77(1):138-144. PMC: 10320126. DOI: 10.1093/cid/ciad132. View

Birkhold M, Mwisongo A, Pollard A, Neuzil K . Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas. J Infect Dis. 2021; 224(12 Suppl 2):S781-S787. PMC: 8687070. DOI: 10.1093/infdis/jiab449. View

Qamar F, Yousafzai M, Dehraj I, Shakoor S, Irfan S, Hotwani A . Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019. Clin Infect Dis. 2020; 71(Suppl 3):S276-S284. PMC: 7705872. DOI: 10.1093/cid/ciaa1323. View

Balasubramanian S, Shah A, Pemde H, Chatterjee P, Shivananda S, Guduru V . Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years. Indian Pediatr. 2019; 55(12):1066-1074. View

Jayaprasad N, Borhade P, LeBoa C, Date K, Joshi S, Shimpi R . Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014-2018. Am J Trop Med Hyg. 2023; 109(3):571-574. PMC: 10484249. DOI: 10.4269/ajtmh.23-0102. View

Mogasale V, Ramani E, Mogasale V, Park J . What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review. Ann Clin Microbiol Antimicrob. 2016; 15(1):32. PMC: 4869319. DOI: 10.1186/s12941-016-0147-z. View

10.

Rodrigues L, Smith P . Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. Epidemiol Rev. 1999; 21(1):56-72. DOI: 10.1093/oxfordjournals.epirev.a017988. View

11.

Farrington C, Manning G . Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990; 9(12):1447-54. DOI: 10.1002/sim.4780091208. View

12.

Tseng K, Joshi J, Shrivastava S, Klein E . Estimating the cost of interventions to improve water, sanitation and hygiene in healthcare facilities across India. BMJ Glob Health. 2020; 5(12). PMC: 7754631. DOI: 10.1136/bmjgh-2020-003045. View

13.

. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019; 19(4):369-381. PMC: 6437314. DOI: 10.1016/S1473-3099(18)30685-6. View

14.

World Health Organization . Typhoid vaccines: WHO position paper, March 2018 - Recommendations. Vaccine. 2018; 37(2):214-216. DOI: 10.1016/j.vaccine.2018.04.022. View

15.

Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A . Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021; 9(11):e1561-e1568. PMC: 8551681. DOI: 10.1016/S2214-109X(21)00346-6. View

16.

Mogasale V, Ramani E, Mogasale V, Park J, Wierzba T . Estimating Typhoid Fever Risk Associated with Lack of Access to Safe Water: A Systematic Literature Review. J Environ Public Health. 2018; 2018:9589208. PMC: 6076975. DOI: 10.1155/2018/9589208. View

17.

Patel P, Patel P, Liang Y, Meiring J, Misiri T, Mwakiseghile F . Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. N Engl J Med. 2021; 385(12):1104-1115. PMC: 8202713. DOI: 10.1056/NEJMoa2035916. View

18.

Date K, Shimpi R, Luby S, N R, Haldar P, Katkar A . Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018. Clin Infect Dis. 2020; 71(Suppl 2):S172-S178. PMC: 7420725. DOI: 10.1093/cid/ciaa597. View

19.

Mohan V, Varanasi V, Singh A, Pasetti M, Levine M, Venkatesan R . Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015; 61(3):393-402. DOI: 10.1093/cid/civ295. View